Our portfolio company Spiral Therapeutics just announced successful completion of the SPT-2101 phase 1b/2a clinical trial for Meniere’s disease, with promising results.
Spiral Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for inner ear disorders. Leveraging its proprietary Minimally Invasive Cochlear System (MICS™), Spiral enables precise, durable, and minimally invasive drug delivery directly to the cochlea. This groundbreaking platform addresses significant unmet medical needs in treating conditions such as hearing loss and balance disorders. Spiral’s therapeutic pipeline includes promising candidates aimed at improving the lives of patients suffering from these challenging conditions.
Key highlights from the trial include:
- Significant reduction in vertigo frequency and severity
- No serious adverse events reported
- Higher dexamethasone exposure linked to improved patient outcomes
Using Spiral’s proprietary Minimally Invasive Cochlear System (MICS™), dexamethasone was precisely delivered to the round window membrane, enabling extended release and enhanced treatment efficacy.
Read the full announcement here.
